| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 45 | 2023 | 651 | 6.910 |
Why?
|
| Immunologic Memory | 47 | 2021 | 283 | 6.480 |
Why?
|
| Lymphocytic choriomeningitis virus | 31 | 2022 | 88 | 3.330 |
Why?
|
| Virus Diseases | 20 | 2016 | 114 | 3.050 |
Why?
|
| Lymphocytic Choriomeningitis | 15 | 2022 | 53 | 2.830 |
Why?
|
| Receptors, Antigen, T-Cell | 14 | 2025 | 281 | 2.770 |
Why?
|
| Influenza A virus | 11 | 2023 | 119 | 2.660 |
Why?
|
| Herpesvirus 4, Human | 10 | 2023 | 178 | 2.380 |
Why?
|
| Epitopes, T-Lymphocyte | 21 | 2019 | 176 | 2.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 11 | 2023 | 119 | 2.030 |
Why?
|
| T-Lymphocytes | 15 | 2024 | 986 | 1.840 |
Why?
|
| Cross Reactions | 23 | 2017 | 127 | 1.630 |
Why?
|
| Vaccinia virus | 13 | 2015 | 70 | 1.620 |
Why?
|
| Immunodominant Epitopes | 8 | 2020 | 56 | 1.550 |
Why?
|
| Vaccinia | 8 | 2010 | 31 | 1.420 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2023 | 89 | 1.410 |
Why?
|
| Viruses | 8 | 2016 | 78 | 1.370 |
Why?
|
| Viral Matrix Proteins | 6 | 2017 | 47 | 1.370 |
Why?
|
| Antigens, Viral | 11 | 2017 | 130 | 1.240 |
Why?
|
| Pichinde virus | 9 | 2022 | 20 | 1.240 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2017 | 244 | 1.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 13 | 2019 | 170 | 1.040 |
Why?
|
| Infectious Mononucleosis | 3 | 2017 | 33 | 0.950 |
Why?
|
| Influenza, Human | 3 | 2017 | 192 | 0.950 |
Why?
|
| Mice, Inbred C57BL | 29 | 2022 | 3231 | 0.940 |
Why?
|
| Immunity, Heterologous | 4 | 2017 | 11 | 0.880 |
Why?
|
| Animals | 59 | 2022 | 19650 | 0.810 |
Why?
|
| Lung | 6 | 2013 | 920 | 0.800 |
Why?
|
| Mice | 41 | 2022 | 10294 | 0.800 |
Why?
|
| Major Histocompatibility Complex | 3 | 2020 | 86 | 0.730 |
Why?
|
| Vaccination | 4 | 2023 | 337 | 0.710 |
Why?
|
| Viral Vaccines | 4 | 2015 | 47 | 0.680 |
Why?
|
| Arenaviridae Infections | 6 | 2022 | 15 | 0.650 |
Why?
|
| Lymphocyte Activation | 13 | 2017 | 743 | 0.630 |
Why?
|
| Immunity | 3 | 2011 | 101 | 0.620 |
Why?
|
| Recombination, Genetic | 1 | 2020 | 238 | 0.610 |
Why?
|
| Peptide Fragments | 6 | 2019 | 400 | 0.600 |
Why?
|
| HLA-A2 Antigen | 8 | 2019 | 64 | 0.570 |
Why?
|
| Viral Proteins | 5 | 2012 | 253 | 0.540 |
Why?
|
| Immune System | 4 | 2013 | 129 | 0.540 |
Why?
|
| Interferon-gamma | 10 | 2017 | 551 | 0.480 |
Why?
|
| Coinfection | 1 | 2015 | 44 | 0.470 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 207 | 0.470 |
Why?
|
| Male | 29 | 2023 | 27747 | 0.470 |
Why?
|
| Humans | 51 | 2025 | 59389 | 0.470 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 5 | 2001 | 70 | 0.460 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2013 | 72 | 0.450 |
Why?
|
| Autoimmunity | 3 | 2011 | 223 | 0.430 |
Why?
|
| Immune Tolerance | 3 | 2013 | 172 | 0.430 |
Why?
|
| Complementarity Determining Regions | 4 | 2023 | 36 | 0.420 |
Why?
|
| Epitopes | 4 | 2023 | 286 | 0.410 |
Why?
|
| Brain | 2 | 2021 | 1488 | 0.410 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 43 | 0.410 |
Why?
|
| Immunity, Cellular | 5 | 2010 | 171 | 0.400 |
Why?
|
| Immunity, Innate | 6 | 2015 | 774 | 0.390 |
Why?
|
| Antibodies | 1 | 2013 | 179 | 0.390 |
Why?
|
| Respiratory Tract Infections | 2 | 2003 | 84 | 0.380 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2010 | 46 | 0.340 |
Why?
|
| Software | 2 | 2025 | 366 | 0.340 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 23 | 0.330 |
Why?
|
| Aging | 1 | 2015 | 710 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 836 | 0.310 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2008 | 6 | 0.310 |
Why?
|
| Orthomyxoviridae | 2 | 2005 | 26 | 0.310 |
Why?
|
| Glycine | 1 | 2008 | 46 | 0.310 |
Why?
|
| Mice, Knockout | 8 | 2021 | 1997 | 0.300 |
Why?
|
| Cricetinae | 6 | 2013 | 366 | 0.300 |
Why?
|
| Peptides | 7 | 2017 | 549 | 0.290 |
Why?
|
| Lymphocytes | 2 | 2005 | 190 | 0.290 |
Why?
|
| Models, Immunological | 5 | 2011 | 85 | 0.290 |
Why?
|
| Nephrology | 1 | 2007 | 15 | 0.280 |
Why?
|
| Computational Biology | 3 | 2025 | 333 | 0.280 |
Why?
|
| Muromegalovirus | 4 | 2017 | 7 | 0.270 |
Why?
|
| Cell Line | 7 | 2013 | 1983 | 0.270 |
Why?
|
| Clone Cells | 6 | 2010 | 106 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 588 | 0.270 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 31 | 0.270 |
Why?
|
| Adolescent | 6 | 2020 | 5838 | 0.270 |
Why?
|
| Flow Cytometry | 6 | 2017 | 645 | 0.260 |
Why?
|
| Apoptosis | 6 | 2014 | 1033 | 0.260 |
Why?
|
| Host-Pathogen Interactions | 3 | 2017 | 240 | 0.250 |
Why?
|
| Kidney Diseases | 1 | 2007 | 169 | 0.250 |
Why?
|
| Computer Simulation | 4 | 2011 | 459 | 0.230 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2023 | 4 | 0.210 |
Why?
|
| H-2 Antigens | 4 | 2014 | 64 | 0.210 |
Why?
|
| Bystander Effect | 1 | 2002 | 5 | 0.200 |
Why?
|
| Nasal Mucosa | 1 | 2001 | 18 | 0.190 |
Why?
|
| Animals, Newborn | 2 | 2021 | 230 | 0.190 |
Why?
|
| Adoptive Transfer | 4 | 2017 | 147 | 0.180 |
Why?
|
| Vaccines | 2 | 2013 | 95 | 0.180 |
Why?
|
| Amino Acid Sequence | 7 | 2025 | 1553 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1479 | 0.170 |
Why?
|
| Cell Cycle | 1 | 2002 | 382 | 0.170 |
Why?
|
| Adult | 7 | 2017 | 15683 | 0.170 |
Why?
|
| Cells, Cultured | 4 | 2014 | 2092 | 0.160 |
Why?
|
| Immediate-Early Proteins | 1 | 2019 | 44 | 0.160 |
Why?
|
| Immunization, Secondary | 2 | 2010 | 40 | 0.160 |
Why?
|
| Young Adult | 3 | 2017 | 4272 | 0.160 |
Why?
|
| Isoantigens | 3 | 2007 | 71 | 0.160 |
Why?
|
| Spleen | 5 | 2014 | 479 | 0.150 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 1951 | 0.150 |
Why?
|
| DNA, Viral | 2 | 2016 | 223 | 0.150 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 446 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2018 | 357 | 0.150 |
Why?
|
| Middle Aged | 5 | 2017 | 16314 | 0.150 |
Why?
|
| Base Sequence | 3 | 2016 | 1302 | 0.150 |
Why?
|
| Female | 10 | 2023 | 30724 | 0.150 |
Why?
|
| Herpesviridae Infections | 2 | 2017 | 25 | 0.150 |
Why?
|
| Trans-Activators | 1 | 2019 | 300 | 0.140 |
Why?
|
| Lymphocyte Count | 5 | 2011 | 68 | 0.140 |
Why?
|
| Viral Load | 3 | 2017 | 220 | 0.140 |
Why?
|
| Antibodies, Viral | 3 | 2016 | 297 | 0.140 |
Why?
|
| Seroconversion | 1 | 2017 | 4 | 0.140 |
Why?
|
| Infant | 2 | 2015 | 1492 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 2 | 2016 | 178 | 0.140 |
Why?
|
| Genome, Viral | 1 | 2018 | 120 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 394 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 623 | 0.130 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1996 | 17 | 0.130 |
Why?
|
| Species Specificity | 2 | 2015 | 329 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2014 | 941 | 0.130 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2016 | 1 | 0.130 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2016 | 2 | 0.130 |
Why?
|
| Poliomyelitis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2001 | 147 | 0.130 |
Why?
|
| Nucleoproteins | 3 | 2006 | 32 | 0.130 |
Why?
|
| Sequence Homology | 1 | 2015 | 20 | 0.120 |
Why?
|
| Cloning, Molecular | 2 | 2015 | 381 | 0.120 |
Why?
|
| Arenaviridae | 1 | 2015 | 1 | 0.120 |
Why?
|
| Vero Cells | 2 | 2006 | 76 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2017 | 331 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 206 | 0.110 |
Why?
|
| Graft Rejection | 2 | 2010 | 289 | 0.110 |
Why?
|
| Oligopeptides | 2 | 2010 | 128 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 48 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2015 | 589 | 0.110 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 218 | 0.110 |
Why?
|
| Aged | 2 | 2023 | 13406 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 118 | 0.110 |
Why?
|
| Amino Acid Motifs | 2 | 2017 | 149 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 661 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2016 | 313 | 0.100 |
Why?
|
| Heat-Shock Proteins | 2 | 1992 | 65 | 0.100 |
Why?
|
| Communicable Disease Control | 1 | 2013 | 37 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2015 | 1284 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 149 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2013 | 85 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 2053 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 527 | 0.100 |
Why?
|
| Immunity, Mucosal | 2 | 2010 | 49 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 450 | 0.090 |
Why?
|
| Vaccines, DNA | 2 | 2010 | 96 | 0.090 |
Why?
|
| Herpes Simplex Virus Vaccines | 1 | 2010 | 1 | 0.090 |
Why?
|
| Herpesvirus 2, Human | 1 | 2010 | 10 | 0.090 |
Why?
|
| Time Factors | 5 | 2011 | 3615 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 1368 | 0.090 |
Why?
|
| Panniculitis | 1 | 2010 | 4 | 0.090 |
Why?
|
| Mice, Congenic | 1 | 2010 | 22 | 0.090 |
Why?
|
| CD3 Complex | 1 | 2010 | 63 | 0.080 |
Why?
|
| Coculture Techniques | 1 | 2010 | 95 | 0.080 |
Why?
|
| Lymphotoxin-alpha | 1 | 2009 | 8 | 0.080 |
Why?
|
| Immunization | 2 | 2001 | 128 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 4 | 2010 | 868 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2011 | 197 | 0.080 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2008 | 5 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1304 | 0.080 |
Why?
|
| Cytokines | 2 | 2003 | 915 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2008 | 17 | 0.080 |
Why?
|
| Hepatitis B Vaccines | 1 | 2008 | 13 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2017 | 1128 | 0.070 |
Why?
|
| Herpes Simplex | 1 | 1988 | 48 | 0.070 |
Why?
|
| Lymphocyte Depletion | 2 | 2001 | 99 | 0.070 |
Why?
|
| Adipose Tissue | 2 | 2002 | 283 | 0.070 |
Why?
|
| Protein Binding | 2 | 2017 | 1555 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2006 | 51 | 0.070 |
Why?
|
| Phenotype | 2 | 2004 | 1137 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2008 | 177 | 0.070 |
Why?
|
| Cell Line, Transformed | 2 | 1999 | 98 | 0.070 |
Why?
|
| Administration, Intranasal | 2 | 2008 | 28 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 1992 | 737 | 0.070 |
Why?
|
| Poly I-C | 2 | 2006 | 76 | 0.070 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2005 | 14 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2006 | 206 | 0.060 |
Why?
|
| Genes, MHC Class I | 1 | 2005 | 27 | 0.060 |
Why?
|
| K562 Cells | 1 | 2005 | 57 | 0.060 |
Why?
|
| Interferons | 1 | 2006 | 61 | 0.060 |
Why?
|
| Cell Death | 2 | 2004 | 271 | 0.060 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2003 | 29 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5119 | 0.060 |
Why?
|
| Mathematical Computing | 1 | 2004 | 11 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2006 | 186 | 0.060 |
Why?
|
| Organ Specificity | 2 | 2003 | 183 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 238 | 0.060 |
Why?
|
| Molecular Docking Simulation | 1 | 2025 | 73 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 446 | 0.060 |
Why?
|
| Integrin alpha1beta1 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2014 | 215 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2004 | 99 | 0.060 |
Why?
|
| Mutation | 1 | 2012 | 2456 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 805 | 0.050 |
Why?
|
| Genes, Viral | 1 | 2003 | 55 | 0.050 |
Why?
|
| Collagen | 1 | 2004 | 115 | 0.050 |
Why?
|
| Fractals | 1 | 2003 | 8 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2003 | 55 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2023 | 33 | 0.050 |
Why?
|
| Succinimides | 1 | 2002 | 17 | 0.050 |
Why?
|
| Fluoresceins | 1 | 2002 | 29 | 0.050 |
Why?
|
| Staining and Labeling | 2 | 2001 | 124 | 0.050 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2001 | 9 | 0.050 |
Why?
|
| Peritoneal Cavity | 1 | 2001 | 31 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 443 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 245 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 196 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2017 | 2903 | 0.040 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 1999 | 6 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2001 | 513 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 244 | 0.040 |
Why?
|
| Virus Replication | 1 | 2001 | 305 | 0.040 |
Why?
|
| Dimerization | 1 | 1999 | 144 | 0.040 |
Why?
|
| Kinetics | 1 | 2001 | 751 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2021 | 228 | 0.040 |
Why?
|
| Cell Movement | 1 | 2001 | 428 | 0.040 |
Why?
|
| Acute Disease | 2 | 2016 | 658 | 0.040 |
Why?
|
| Survival Rate | 1 | 2001 | 801 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 552 | 0.040 |
Why?
|
| Antibody Formation | 2 | 2008 | 108 | 0.040 |
Why?
|
| Cell Survival | 2 | 2014 | 559 | 0.040 |
Why?
|
| Necrosis | 1 | 1998 | 140 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2018 | 80 | 0.040 |
Why?
|
| Macrophages | 1 | 2003 | 1015 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 676 | 0.040 |
Why?
|
| Convalescence | 1 | 2016 | 18 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2017 | 104 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 75 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 226 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2017 | 145 | 0.030 |
Why?
|
| Phylogeny | 1 | 2018 | 337 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 263 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2017 | 253 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2016 | 288 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 495 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2016 | 40 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 617 | 0.030 |
Why?
|
| Virus Latency | 2 | 2009 | 29 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 424 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1552 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2016 | 260 | 0.030 |
Why?
|
| Genomics | 1 | 2018 | 319 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2014 | 30 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 345 | 0.030 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 28 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 1994 | 53 | 0.030 |
Why?
|
| Thymocytes | 1 | 2014 | 19 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 48 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2014 | 145 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1051 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 717 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2014 | 169 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1504 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 1992 | 19 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 33 | 0.020 |
Why?
|
| Oligodendroglia | 1 | 1991 | 33 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1992 | 164 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 472 | 0.020 |
Why?
|
| Interdisciplinary Studies | 1 | 2011 | 7 | 0.020 |
Why?
|
| Administration, Mucosal | 1 | 2010 | 2 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 809 | 0.020 |
Why?
|
| Microbial Viability | 1 | 2011 | 57 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2010 | 67 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 40 | 0.020 |
Why?
|
| Vagina | 1 | 2010 | 79 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 100 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1992 | 689 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 2010 | 100 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1991 | 220 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2011 | 143 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 554 | 0.020 |
Why?
|
| Manitoba | 1 | 1988 | 2 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 1991 | 207 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 100 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2006 | 10 | 0.020 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2005 | 16 | 0.020 |
Why?
|
| HIV Infections | 1 | 2011 | 913 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 20 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2003 | 57 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1988 | 2375 | 0.010 |
Why?
|
| Pregnancy | 1 | 1988 | 2213 | 0.010 |
Why?
|
| Hemorrhagic Fever, American | 1 | 2001 | 1 | 0.010 |
Why?
|
| Hemocyanins | 1 | 2001 | 22 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 46 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 32 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 184 | 0.010 |
Why?
|
| Antigens | 1 | 2001 | 146 | 0.010 |
Why?
|
| Stem Cells | 1 | 2001 | 255 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 808 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1988 | 6071 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 1995 | 104 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1995 | 303 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 1992 | 28 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1992 | 65 | 0.010 |
Why?
|
| Integrins | 1 | 1992 | 106 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1992 | 343 | 0.010 |
Why?
|
| Epilepsy | 1 | 1991 | 105 | 0.010 |
Why?
|
| Models, Biological | 1 | 1991 | 1143 | 0.000 |
Why?
|